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SUMMARY
Drug-resistant epileptic encephalopathies of infancy have been associated with
KCNT1 gain-of-function mutations, which increase the activity of KNa1.1 so-
dium-activated potassium channels. Pharmacological inhibition of hyperactive
KNa1.1 channels by quinidine has been proposed as a stratified treatment, but
mostly this has not been successful, being linked to the low potency and lack of
specificity of the drug. Here we describe the use of a previously determined
cryo-electron microscopy-derived KNa1.1 structure and mutational analysis to
identify how quinidine binds to the channel pore and, using computational
methods, screened for compounds predicated to bind to this site. We describe
six compounds that inhibited KNa1.1 channels with low- and sub-micromolar po-
tencies, likely also through binding in the intracellular pore vestibule. In hERG in-
hibition and cytotoxicity assays, two compounds were ineffective. These may
provide starting points for the development of new pharmacophores and could
become tool compounds to study this channel further.
INTRODUCTION
Gain-of-function mutations in the KCNT1 gene are associated with severe, drug-resistant forms of child-
hood epilepsy (Barcia et al., 2012; Heron et al., 2012). Epilepsy of infancy with migrating focal seizures
(EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) were the first disorders found
to be associated with KCNT1, with the more recently described Ohtahara syndrome (Martin et al., 2014),
West syndrome (Ohba et al., 2015), Lennox-Gastaut syndrome (Jia et al., 2019), and sleep-related hyper-
motor epilepsy (Cataldi et al., 2019; Rubboli et al., 2019). In addition to frequent seizures, patients may
also present developmental delay and psychiatric and intellectual disabilities (Gertler et al., 2018; Lim et
al., 2016). KCNT1 encodes a sodium-activated potassium channel subunit, KNa1.1, which has previously
been termed SLACK and Slo2.2 (Joiner et al., 1998; Yuan et al., 2003). Similar to other potassium channels,
the functional proteins are formed by a tetramer of subunits, each of which possesses six transmembrane
alpha helices, a re-entrant pore loop between the fifth and sixth helix that forms the selectivity filter, and
two intracellular regulation of conductance of potassium (RCK) domains (Hite et al., 2015). KNa1.1-contain-
ing channels are expressed throughout the central nervous system (Bhattacharjee et al., 2002; Rizzi et al.,
2016) and are believed to have a stabilizing effect on the membrane potential following sodium influx dur-
ing neuronal excitation (Budelli et al., 2009; Cervantes et al., 2013; Hage and Salkoff, 2012; Liu and Stan
Leung, 2004; Nanou et al., 2008). Virtually all epilepsy-associated KCNT1mutations increase channel activ-
ity, although why epilepsy should arise is not understood, since potassium channel opening is usually asso-
ciated with a decrease in neuronal excitability. One proposedmechanism, based on studies of human stem
cell-derived neurons harboring one such mutation, is that hyperexcitability can be caused by an enhanced
sodium-dependent after-hyperpolarization, facilitating an increase in the rate of action potential firing
(Quraishi et al., 2019).
Quinidine is a class I antiarrhythmic agent, which exerts its effects by non-selectively inhibiting cardiac
cation channels at micromolar concentrations. Notably, quinidine also inhibits KNa1.1 channels (Yang
et al., 2006), including those harboring epilepsy-causing mutations, at similar concentrations, leading to
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the hypothesis that quinidine could reverse the gain of function and treat KCNT1-associated epilepsy (Mi-
kati et al., 2015; Milligan et al., 2014). Limited improvement has been achieved in a small number of patients
using quinidine therapy, but in the majority of cases it is ineffective (Chong et al., 2016; Fitzgerald et al.,
2019; Madaan et al., 2018; McTague et al., 2018; Mikati et al., 2015; Mullen et al., 2018). The lack of selec-
tivity and low potency of quinidine in inhibiting KNa1.1 channels, with IC50 values in the order of 0.1 mM
(Rizzo et al., 2016; Yang et al., 2006), in the central nervous system without significantly affecting cardiac
function is a concern and limits the dosing levels of quinidine (Mullen et al., 2018). Moreover, there is still
a paucity of information on the binding site and the mode of action of KNa1.1 inhibitors. Other reported
inhibitors of KNa1.1 are bepridil (Yang et al., 2006) and clofilium (de Los Angeles Tejada et al., 2012),
both of which also have inhibitory effects on cardiac cation channels. The identification of alternative drugs
that better target KNa1.1 are therefore desired (Mikati et al., 2015; Milligan et al., 2014). The mechanisms by
which these three drugs inhibit potassium channels, hERG in particular, have been studied previously and
involve direct block of the pore via the intracellular vestibule and are coordinated by aromatic side-chains,
such as phenylalanine (Kamiya et al., 2006; Knape et al., 2011; Macdonald et al., 2018; Perry et al., 2004;
Wrighton et al., 2015).
With the development of direct electron detectors, more powerful microscopes, and improved data pro-
cessing software, there has been an expansion of the use of cryo-electron microscopy (cryo-EM) and single
particle analysis to determine high-resolution structures of membrane proteins (Rawson et al., 2016). By-
passing the need to crystallize membrane protein samples makes this approach particularly attractive.
One of the first high-resolution ion channel structures determined by cryo-EMwas the chicken KNa1.1 chan-
nel, initially described at 4.5 A˚ resolution (Hite et al., 2015), with the inactive and activated conformations
subsequently resolved to 4.3 and 3.8 A˚, respectively (Hite and MacKinnon, 2017). The increase in resolution
enables the generation of molecular models, which presents new opportunities that can be utilized in com-
puter-aided drug discovery (CADD) or in silico drug design. To discover new therapies for rare disorders,
such as those caused by KCNT1 mutations, efficiencies of drug development cost and time are required
(Swinney and Xia, 2014). Computer-aided approaches, such as virtual screening, can help reduce the
need for functional screening of large compound sets by predicating which chemicals are likely to occupy
a defined binding site (Lin et al., 2020).
In this study, we used the cryo-EM-derived structures of the KNa1.1 channel to model quinidine binding in
silico, having hypothesized that it blocks the channel pore, similar to its interaction with hERG. Having iden-
tified the intracellular pore vestibule as the likely site for known inhibitors to bind, we then conducted virtual
high-throughput screening of a library of commercially available compounds with the view of identifying
more potent and selective binders. We now report the identification of six diverse compounds that inhibit
KNa1.1 more potently than the quinidine.
RESULTS
Identification of Inhibitor Binding Site in the KNa1.1 Channel Pore
In the absence of potent and selective inhibitors of KNa1.1 potassium channels, we sought to use compu-
tational approaches to identify inhibitors with improved properties. To identify a region in the KNa1.1 struc-
ture to focus in silico screening, we first sought to identify how compounds known to inhibit the channel
exert their effects. Hypothesizing that both quinidine and bepridil inhibit channels by occupying the inner
pore vestibule we created a minimal structural model of the channel pore by removing the S1 to S4 and the
cytosolic domains of the cryo-EM structures of the ‘‘closed’’ and ‘‘open’’ chicken KNa1.1 channel (Hite and
MacKinnon, 2017). This left the S5, pore loop, and S6 of each subunit, which is highly conserved between
chicken and human KNa1.1. Using automated procedures, both inhibitors were docked into the pore in its
closed conformation at two distinct sites: in the vicinity of the equivalent positions of F346 and M354 in the
S6 segment of the human isoform (Figure 1A). In contrast, using the model of the open conformation,
Figure 1. Molecular Docking of Inhibitors and Functional Analysis of Mutant KNa1.1 Channels Used in This Study
(A) Docking of quinidine and bepridil (yellow) into the KNa1.1 pore domain, comprising the S5, P loop, and S6 of the closed and open conformational states
(gray); side chains equivalent to F346 (magenta) and M354 (cyan) of the human KNa1.1 homolog are indicated.
(B and C) (B) Representative whole-cell currents and (C) mean (GSEM, n = 5–9 cells) current-voltage plots from non-transfected (NT) HEK 293 cells and cells
transfected with wild-type (WT), pore mutant (F346S, F346I, M354S, M354I), or disease-causing mutant (Y796H) KNa1.1.
(D) Mean current amplitude at 0 mV from the data in (C); *p < 0.05, **p < 0.005 compared with WT, independent one-way ANOVA with Games-Howell post
hoc test.
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quinidine and bepridil could only be docked to the site involving F346 (Figure 1A). To validate the docking,
both residues (F346 andM354) of human KNa1.1 were mutated to isoleucine and serine (Figures 1B and 1C)
and inhibition by quinidine and bepridil was evaluated further. Mutation of M354 had modest effects, with
no significant effect on potency of quinidine, but the mutation of F346 to I346 reduced the potency approx-
imately 10-fold (Figure 2). We found that mutating these pore residues, particularly F346, also increased
channel activity, with respect to current amplitude and reduced current rectification (Figures 1B–1D). To
exclude the possibility that increased channel activity was not the cause of the reduced efficacy of the
Figure 2. Concentration-Inhibition Analysis of Wild-Type and Mutant KNa1.1 Channels by Quinidine and Bepridil
(A) Representative currents evoked by voltage ramps from cells expressing WT or mutant KNa1.1 with increasing
concentrations of quinidine as indicated.
(B) Mean (GSEM) concentration-inhibition plots for wild-type and mutant KNa1.1 channels in response to 3 mM to 1 mM
quinidine. Mean (GSEM) IC50 for WT, 124.99 G 34.52 mM (n = 5 cells); F346I, 736.08 G 94.09 mM (n = 5); F346S, 1.23 G
0.19 mM (n = 4); M354I, 99.23 G 49.61 (n = 5); M354S, 247.16 G 19.96 mM (n = 5); Y796H, 38.00 G 12.89 mM (n = 5).
(C) Mean (GSEM) concentration-inhibition plots for wild-type and mutant KNa1.1 channels in response to 0.3–100 mM
bepridil. IC50 for WT, 6.36 G 2.12 mM (n = 5); F346I, 35.91 G 11.01 mM (n = 4); F346S, 23.43 G 5.17 mM (n = 5).
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inhibitors, for example, through preferential block of the closed state, their effects on a disease-causing
gain-of-function mutation, Y796H (Heron et al., 2012), was explored. This mutation causes an amino acid
substitution in a KNa1.1 intracellular region distal to the pore domain and caused a large increase in
KNa1.1 channel activity (Figures 1B–1D). In contrast to the pore mutants, quinidine inhibited this mutant
channel with a 3-fold increase in potency (Figure 2B).
Virtual Screening and Validation of KNa1.1 Inhibitors
Having identified the internal vestibule, just below the selectivity filter, as the likely site for inhibitor binding,
we used this region in the minimal pore structure of the open channel conformation to dock compounds
using in silico screening and a diverse library of 100,000 drug-like molecules. This approach was comple-
mented by computational identification of compounds with structural similarity to bepridil, the most
potent of the known inhibitors of KNa1.1, and then also docking these compounds into the structure of
the KNa1.1 channel pore. Both computational techniques resulted in a list of compounds, ranked by their
docking score and predicted binding affinities. A selection of 17 compounds (details in Table S1), based on
their ranking and commercial availability, were then obtained and evaluated for their ability to inhibit hu-
man KNa1.1 channels expressed in HEK cells. At 10 mM, six of the compounds inhibited KNa1.1 currents by at
least 40% and were selected for further analysis (Figure 3A). Initially, and to validate inhibition in the inner
pore vestibule, we tested the ability of these compounds to inhibit F346S KNa1.1, which had showed
reduced sensitivity to both quinidine and bepridil. At 10 mM, the degree by which F346S KNa1.1 was in-
hibited by each compound was reduced, compared with WT KNa1.1 (Figure 3A). Concentration-inhibition
analysis (Figures 3B–3D) yielded mean IC50 concentrations ranging from 0.6 to 7.4 mM with WT KNa1.1. In
comparison, quinidine and bepridil inhibitedWT KNa1.1 with IC50 values in the order of 125 mM and 6.4 mM,
respectively (Figures 2 and 3D). Inspection of the inhibitors docked into the KNa1.1 pore domain suggests
that binding involves both hydrophobic interactions with S6 pore-lining residues and hydrogen-bonding
with P loop residues (Figure 4 and Table S1).
The nature of the inhibition by these compounds was explored further. To be used therapeutically, KNa1.1
inhibitors would be required to inhibit channels that have epilepsy-causing amino acid substitutions. We
therefore explored the potency of the inhibitors with Y796H KNa1.1 gain-of-function mutation. Each of
the six compounds inhibited the mutant channels, but in this experiment BC7 and BC14 were significantly
less potent (Figures 3B–3D and S1). We also explored the importance of chemical groups in channel inhi-
bition, using BC12 as an example, for which several analogues were commercially available. Each analogue
failed to reduce WT KNa1.1 channel currents by more than approximately 10% at 10 mM and were deemed
inactive (Figure S2).
Preliminary Toxicological Assessment of KNa1.1 Channel Inhibitors
Finally, to anticipate toxicological effects of these compounds, should they or derivatives be developed
further, we studied their effects on hERG potassium currents and in a cellular toxicity assay. Frommeasure-
ments of tail current amplitudes, 10 mM BC5, BC6, and BC7 almost completely inhibited hERG channels
expressed in HEK 293 cells (>80%, Figures 5A and 5B). In contrast, BC14 had a partial effect (approximately
45%) at the same concentration, whereas BC12 and BC13 were even less effective, reducing currents by
approximately 10%–20%. In cytotoxicity assays, which involved exposing HEK 293 cells to compounds
for 24 h, only BC7 exhibited a concentration-dependent reduction in cell viability, at concentrations of
1 mM and above (Figure 5C). With BC5, B6, and BC14, a reduction in cell viability was found at concentra-
tions an order of magnitude higher than the IC50, whereas BC12 and BC14 had no effect at all concentra-
tions tested, up to and including 100 mM (Figure 5C). Blasticidin (10 mg/mL) and DMSO (10% v/v) reduced
cell viability in the order of 45% and 90%, respectively.
DISCUSSION
Analysis of compounds identified as potential KNa1.1 inhibitors by in silico docking yielded six previously
unknown inhibitors, each more potent than quinidine that has been trialed clinically as a stratified treat-
ment for KCNT1-associated epilepsy. These inhibitors are structurally diverse and there is no clear pharma-
cophore, although BC6 and BC7 are among the scaffolds with structural similarity to bepridil. We propose
that each of these compounds, in addition to quinidine and bepridil, inhibits the channel by blocking the
pore via the intracellular vestibule. This is indicated by the reduced efficacy of each compound with the
F346S pore mutation, and which is likely to be independent of the increased channel activity caused by
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Figure 3. Functional Evaluation of Top-Scoring Molecules from In Silico Docking
(A) Mean (GSEM, n = 3–4 cells) WT KNa1.1 conductance measured as the slope of the current evoked by depolarizing voltage ramps, relative to baseline, in
the presence of 10 mM test compound; with those that were active (right of dashed line) counter-tested with F346S KNa1.1 poremutant (*p < 0.05, **p < 0.005,
***p < 0.0005, t test.).
(B and C) (B) Representative traces and (C) mean (GSEM, n = 5–7 cells) concentration-inhibition plots for active inhibitors.
(D) Summary table with mean (GSEM) potencies of compounds inhibiting WT and Y796H KNa1.1 (n = 5–7 cells). *p < 0.05 versus potency with WT KNa1.1
(Student t test).
See also Table S1, Figures S1 and S2.
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the mutation, since with quinidine there was no similar loss of efficacy with Y796H, an epilepsy-causing mu-
tation distal from the pore. The effects of mutations of F346 are somewhat modest, yielding a 10-fold
decrease in potency, compared with WT KNa1.1, suggesting that other interactions are necessary, but
are consistent with the hypothesis that inhibitors block the channel by occupying the inner vestibule of
the pore. This residue is also at the equivalent position in the S6 segment as F656 in hERG that co-ordinates
inhibitor binding of quinidine, bepridil, and clofilium (Kamiya et al., 2006; Macdonald et al., 2018; Perry
et al., 2004). This mode of action requires the inhibiting compound to traverse the plasma membrane
and enter the pore via the cytoplasm. It is noteworthy that each of the compounds tested that had a
Figure 4. Chemical Structures of Inhibitors (Magenta) and Their Docked Poses in the KNa1.1 Pore Domain
Side chains at positions equivalent to the human isoform are indicated (pink): T314 in the P loop and F346 andM354 in the
S6 segment of human KNa1.1. For clarity, the compounds are shown above each panel for the inhibitors analyzed in
Figure 3.
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calculated logP (cLogP) value of 3.2 or less did not exhibit inhibition of KNa1.1, and this may have been a
result of poor membrane permeability. By using a model of the ion channel pore that is putatively in the
open conformation, we had anticipated that inhibitors identified through docking would achieve similar
or even higher potency with the Y796H mutant KNa1.1, but this was not always the case. It is possible
Figure 5. Preliminary Toxicological Assessment of KNa1.1 Channel Inhibitors
(A) Representative hERG whole-cell currents recorded from a transfected HEK 293 cell in the absence (control) and
presence of 10 mM inhibitor, as indicated.
(B) Mean (GSEM, n = 3) tail current at 50 mV remaining in the presence of each inhibitor.
(C) Cytotoxicity assays indicating mean (GSEM, n = 3) viability of HEK 293 cells using WST reagent following overnight
exposure to inhibitor at the indicated concentrations, with 10 mM blasticidin and 10% v/v DMSO as positive controls; *p <
0.05, **p < 0.005, ***p < 0.0005, independent one-way ANOVA with Dunnett’s post hoc test.
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that the apparent decrease in potency of some of the compounds with Y796Hmay be attributed to the high
level of basal channel activity with this mutant channel and incomplete series resistance compensation. This
could underestimate channel inhibition at the lower concentrations and increase variability. The increase in
potency of quinidine with Y796H, relative to WT KNa1.1, however, is consistent with previous studies of
other gain-of-function mutations (Rizzo et al., 2016).
It may have been possible to obtain inhibitors by testing compounds identified through computational
tools to have structures similar to the known inhibitors, quinidine, bepridil, and clofilium, but without using
molecular docking. The risk with this approach is that the compounds may also have similar potency in in-
hibiting cardiac ion channels, which would preclude their further development. Indeed, this is what we
found with BC6 and BC7, which both almost completely inhibited hERG currents at 10 mM. Instead, by dock-
ing a diverse library, we were able to identify compounds that were structurally distinct from the known in-
hibitors and that included some that had little effect on hERG at 10 mM. Together, this highlights the impor-
tance of screening a wide range of compounds, which in our approach employed virtual screening using
computational approaches instead of a high-throughput cell-based functional screen. Other sites in the
channel protein could potentially be used to target molecular docking and virtual screening, which may
enhance KNa1.1 selectivity over other ion channels, but there is presently a lack of understanding of how
other KNa1.1 domains could be targeted pharmacologically to modulate channel function.
Although the cryo-EM structures indicate that activation by sodium involves an expansion of the intracel-
lular pore vestibule (Hite and MacKinnon, 2017), functional experiments with this and the closely related
KNa1.2 and KCa1.1 (BKCa) channels point to the selectivity filter and proximal hydrophobic residues, rather
than an S6 helix bundle, as the location of the channel gate (Garg et al., 2013; Giese et al., 2017; Jia et al.,
2018; Suzuki et al., 2016). This means that the inhibitors described here block at the channel gate and this
should be a mode of inhibition that is efficacious with virtually all clinical gain-of-function mutations, inde-
pendent of the mechanism by which increased open probability is achieved, rather than an inhibitor that
binds to modulatory sites. An exception, however, may be F346L that was identified in a patient with EIMFS
(McTague et al., 2018), which, based on our findings with mutations generated at this site in the pore, may
have reduced inhibitor sensitivity. Indeed, it was found that F346L KNa1.1 channels expressed in Xenopus
oocytes were resistant to block by 300 mM quinidine (McTague et al., 2018), although the pharmacological
effects of quinidine on channels containing a mixture of F346L and wild-type subunits, to mimic the hetero-
zygous disorder, has not been explored.
Notwithstanding our preliminary efforts to characterize the potential toxicity of these inhibitors by studying in-
hibition of hERG channel currents and the effects in cell viability assays, we are unable to make any statement
regarding their selectivity or safety ahead of any in vitro or in vivo investigation. Since the computational
approachwas basedon the inhibition by quinidine andbepridil, onemight expect a similar rangeof ion channels
tobe inhibitedby the compoundsdescribedhere.However, the low level of inhibition of hERGat 10mMbyBC12
and BC13 suggests that across the compounds there may be varying levels of selectivity, which could be further
improved by synthesis and analysis of derivative compounds and testing their effects on a range of different
cation channels. We do note, however, the characteristics of pan-assay interference (PAINS) in compounds
BC6, BC7, and BC13, owing to the presence of the conjugated carbonyl group, meaning there may be non-spe-
cific effects in other functional assays. The lack of effects of the four analogues of BC12 tested demonstrates the
potential for generating an inhibitor pharmacophore from this compound; thus, these may provide starting
points for the development of more potent inhibitors.
The generation of high-resolution structural data by cryo-electron microscopy and single particle analysis
has had a significant impact in structural biology. Importantly, circumventing the need to crystallize sam-
ples means that membrane proteins are more amenable to analysis, and also that human proteins, rather
than homologs from prokaryotes and lower eukaryotes, now featuremore prominently. This means that, for
in silico analysis and drug discovery, target proteins very close to human, if not the human protein itself, can
be utilized. The pore domain of the chicken KNa1.1 subunit, however, is virtually identical to that of the hu-
man homolog, and we demonstrate its suitability for in silico docking experiments to provide potential in-
hibitors to characterize using a functional assay. Our study, in addition to identifying KNa1.1 inhibitors from
a compound library, provides a further example of the use of cryo-electron microscopy-generated mem-
brane protein structural data in identifying new small molecule inhibitors through a structure-based discov-
ery approach.
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Limitations of the Study
A structure of the human KNa1.1 channel was not available, so we employed that of the chicken homolog.
The channel domain used for the docking experiments is highly conserved between chicken and human
KNa1.1, and the specific residues discussed are conserved. By restricting the docking experiments to the
intracellular pore vestibule of the channel, to decrease computational complexity, we disregarded poten-
tial interactions of compounds with other parts of the protein.
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Table S1. Details of compounds tested, Related to Figures 3 and 4: Top-scoring compounds 
identified through virtual high-throughput screening or #bepridil overlay, assessed for KNa1.1 
inhibition at 10 μM. *Compounds that demonstrated >40% inhibition and were studied further. The 
predicted H-bonds use the amino acid sequence in the chicken KNa1.1 structure (PDB: 5U70), 
with corresponding positions in human KNa1.1 in parentheses. 
 
BC ID PubChem 
ID 
Chembridge 
ID 
M.W. cLogP Docking score Predicted H-bond 
1 42211371 10226003 433.5 2.1 -8.731 
 
E326 (E347) 
T293 (T314) x2 
2 42170356 18717381 450.5 2.611 -8.841 T293 (T314) 
S392 (S313) 
3 
 
45198665 32500723 489.5 1.76 -9.151 T293 (T314) x2 
4 72869676 38250229 360.4 2.9 -8.88 
 
T293 (T314) x2 
5* 42481567 38627778 491.5 4.154 -9.607 T293 (T314) 
F291 (F312) 
6#* 1283470 5143781 413.3 4.81 -7.44 
 
T293 (T314) 
7#* 2272824 5214461 412.2 7.05 -7.189 
 
T293 (T314) x2 
8# 1376211 5422905 359.5 6.26 -7.246 
 
n/a 
9# 5341073 5574034 423.3 6.67 -7.28 
 
T293 (T314) 
10 5342180 5690314 459.5 6.64 -9.022 F291 (F312) 
T293 (T314) x2 
11 
 
56902153 60526468 324.4 3.21 -9.074 F291 (F312) 
12* 1330052 7040211 467.4 5.37 -8.732 
 
F291 (F312) 
T293 (T314) x2 
13* 
 
2185932 7364411 253.3 3.906 -8.891 F291 
14* 1243440 7942343 455.5 5.214 -8.891 
 
n/a 
15 72922744 84082349 359.4 1.15 -8.638 
 
F291 (F312) 
T293 (T314) x2 
16 70780443 
 
90931265 327.4 1.83 -8.74 F291 (F312) 
17 25249672 9273389 260.4 3.085 -8.861 
 
F291 (F312) 
 
  
 Figure S1. Functional evaluation of novel inhibitors with KNa1.1 channels harbouring the 
epilepsy-causing mutation Y796H, Related to Figure 3. A Representative traces and B mean 
(± SEM, n= 5 to 7 cells) concentration-inhibition plots for active inhibitors. C  Mean (± SEM, n= 5 
to 7 cells) potencies of compounds inhibiting Y796H KNa1.1; quinidine data from Figure 2. 
 Figure S2: Evaluation of compounds simlar to BC12, Related to Figure 3. A Mean (± SEM, 
n = 3) KNa1.1 conductance, measured as the slope of the current evoked by a depolarising 
voltage ramp in the presence of 10 µM test compound relative to control solution. B Chemical 
structures of compounds tested, their computed LogP (cLogP) and Glide docking score. 
 Transparent Methods 
Model preparation and molecular docking 
Models of the KNa1.1 pore domain were generated in UCSF Chimera using the atomic models of 
the putative closed and open tetrameric channel conformations (PDB:5U76 and 5U70, 
respectively (Hite and MacKinnon, 2017)), and comprised residues 244 to 340 
(S244AMF…LWME334) of each subunit. Automated docking was conducted using SwissDock 
(Grosdidier et al., 2011) and GLIDE (Friesner et al., 2004) in Maestro (Schrödinger). With 
SwissDock, docking of quinidine and bepridil was carried out using the entire model of the pore 
domain. Virtual high-throughput screening was performed using GLIDE with the model of the pore 
domain in the putative open conformation, targeting a 20 x 20 x 20 Å square box that enclosed 
side chains from both the selectivity filter and S6 transmembrane segment that line the 
intracellular pore vestibule. Both protein and ligand-based docking approaches were used. 
Initially, a Chembridge library consisting of 100,000 drug-like screening compounds were 
screened in HTVS mode, ranked according to their predicted binding affinities, and the top-scoring 
10,000 compounds were then docked using the higher precision SP mode. Approximately 100 
top-scoring compounds were visually inspected using PyMOL to identify the binding interactions 
with the protein. For the ligand-based approach, ROCS (Hawkins et al., 2007) was used to overlay 
the Chembridge library of compounds over the predicted bepridil binding pose. Compounds that 
were predicted to overlay with bepridil were subsequently docked, as above, into the inner pore 
vestibule and were analysed to determine whether they would form interactions with the protein. 
The structures of the best scoring compounds from both approaches were analysed to determine 
the ‘drug-like’ properties of the molecules. Of the top-scoring compounds which fit the criteria, 17 
were ordered from Chembridge (Chembridge Corp., San Diego, CA) and were shipped as dry 
stocks in 1 or 5 mg quantities before being dissolved in dimethylsulphoxide to stock concentration 
of 10 mM. 
 
Molecular biology and cell culture 
A full-length KNa1.1 cDNA clone (IMAGE: 9054424; Genbank BC171770.1) was obtained (Source 
Bioscience, Nottingham, U.K.) and the coding region subcloned into the pcDNA6-V5/His6 vector 
(Invitrogen). Mutations were introduced by the polymerase chain reaction using the New England 
BioLabs mutagenesis method and confirmed by sequencing (Genewiz, Takeley, U.K.). Due to the 
large size and high GC content of the insert, some mutations were generated in a plasmid 
containing the Bsu36I/BspEI (pore mutants) or SbfI/BsiWI (Y796H) restriction fragment, and then 
subcloned into the corresponding sites in the pcDNA6-KNa1.1 construct. Human embryonic kidney 
(HEK 293) cells were cultured in Dulbecco’s modified Eagle medium (DMEM with GlutaMax, 
Invitrogen), supplemented with 10% v/v foetal bovine serum, 50 U/ml penicillin, and 0.05 mg/ml 
streptomycin. Cells were co-transfected with pcDNA6-KNa1.1 and pEYFP-N1 plasmid DNA using 
Mirus TransIT-X2 reagent (Geneflow, Lichfield, U.K.) and were plated onto borosilicate glass 
cover slips for electrophysiological experiments, which were conducted 2 to 4 days later. 
 
Electrophysiology 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich (Gillingham, U.K.). 
Patch pipettes were pulled from thin-walled borosilicate glass (Harvard Apparatus Ltd, 
Edenbridge, Kent, UK), polished, and gave resistances of 1.5 to 2.5 MΩ in the experimental 
solutions.  The pipette solution contained, in mM, 100 K-Gluconate, 30 KCl, 10 Na-Gluconate, 29 
Glucose, 5 EGTA and 10 HEPES, pH 7.3 with KOH and the bath solution contained, in mM, 140 
NaCl, 1 CaCl2, 5 KCl, 29 Glucose, 10 HEPES and 1 MgCl2, pH 7.4 with NaOH. Currents were 
recorded from fluorescing cells at room temperature (20 to 22 oC) using the whole-cell patch 
clamp configuration using an EPC-10 amplifier (HEKA Electronics, Lambrecht, Germany), with 
>65 % series resistance compensation (where appropriate), 2.9 kHz low-pass filtering, and 10 
kHz digitisation. For current-voltage analysis, cells were held at -80 mV and 400 ms pulses were 
applied to voltages between -100 and 80 mV. To evaluate inhibition by compounds, cells were 
held at -80 mV and 500 ms voltage ramps were applied from -100 to 40 mV at 0.2 Hz. Initially 
compounds, which were delivered by gravity perfusion, were applied serially at 10 µM (0.1 % final 
DMSO content) for 2 min, followed by at least 2 min wash with control solution before the next 
compound was added. Those compounds that that exhibited at least 40% current inhibition were 
analysed further by concentration-inhibition analysis: G/GC = (1 + ([B]/IC50)H)-1 + c, where G is the 
conductance measured as the slope of the current evoked by the voltage ramp in the presence 
of the inhibitor, IC is the control conductance in the absence of inhibitor, [B] is the concentration 
of the inhibitor, IC50 the concentration of inhibitor that yields 50% inhibition, H the slope factor, 
and c the residual current. For hERG currents, cells were held at -80 mV and 4 s depolarising 
pulses to +40 and then -50 mV were applied at 0.2 Hz.  Data were analysed using Fitmaster 
(HEKA Electronics, Lambrecht, Germany), Microsoft Excel, and OriginPro 7.5 (OriginLab 
Corporation, Northampton, MA, USA). Data are presented as means ± SEM (n = number of cells). 
Statistical analysis was carried out using SPSS (IBM analytics, Portsmouth, UK) with p<0.05 
being considered significant. 
 
Cytotoxicity assay 
Non-transfected HEK 293 cells were seeded at a density of 5x104 cells/ well in culture medium in 
a 96-well plate and incubated overnight at 37 °C in 5% CO2. Following exposure to three different 
concentrations of inhibitor for 24 hours, WST-1 reagent (Source Bioscience, Nottingham, U.K.) 
was added and cells were incubated for a further 2 hours. Inhibitor concentration ranges were 
selected to make comparison with effects on KNa1.1 currents. Cells were also treated with 10% 
v/v DMSO or 10 µg/ml blasticidin as positive controls. Absorbance at 450 nm (reference 650 nm) 
was measured using the Flexstation 3 microplate reader (Molecular Devices, Wokingham, UK). 
Cell viability was calculated as a percentage of the absorbance measured from untreated cells. 
Data were analysed using Microsoft Excel and OriginPro 7.5 (OriginLab Corporation, 
Northampton, MA, USA). Data are presented as mean ± SEM (n = number of independent 
experiments). Statistical analysis was carried out using SPSS. Data were compared using an 
independent one-way ANOVA with Dunnett’s post-hoc test; p<0.05 was considered significant. 
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